$2.40
0.00% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US92337C1045
Symbol
VSTM
Sector
Industry

Verastem, Inc. Stock price

$2.40
+0.06 2.56% 1M
-10.29 81.09% 6M
-5.74 70.52% YTD
-7.56 75.90% 1Y
-30.48 92.70% 3Y
-12.36 83.74% 5Y
-111.48 97.89% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.00 0.00%
ISIN
US92337C1045
Symbol
VSTM
Sector
Industry

Key metrics

Market capitalization $96.58m
Enterprise Value $76.23m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.62
P/S ratio (TTM) P/S ratio 9.66
P/B ratio (TTM) P/B ratio 3.42
Revenue (TTM) Revenue $10.00m
EBIT (operating result TTM) EBIT $-98.78m
Free Cash Flow (TTM) Free Cash Flow $-102.18m
Cash position $83.37m
EPS (TTM) EPS $-3.34
P/E forward negative
P/S forward 14.49
EV/Sales forward 11.43
Short interest 4.91%
Show more

Is Verastem, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Verastem, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Verastem, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Verastem, Inc. forecast:

Buy
100%

Financial data from Verastem, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
10 10
-
100%
- Direct Costs 0.02 0.02
82% 82%
0%
9.98 9.98
9,173% 9,173%
100%
- Selling and Administrative Expenses 37 37
35% 35%
365%
- Research and Development Expense 72 72
54% 54%
722%
-99 -99
33% 33%
-988%
- Depreciation and Amortization 0.02 0.02
82% 82%
0%
EBIT (Operating Income) EBIT -99 -99
33% 33%
-988%
Net Profit -89 -89
19% 19%
-895%

In millions USD.

Don't miss a Thing! We will send you all news about Verastem, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verastem, Inc. Stock News

Positive
Seeking Alpha
2 days ago
Verastem's Avutometinib and Defactinib combination therapy targets recurrent LGSOC and is expected to complete its rolling NDA by 2H2024. The company has a diverse pipeline, exploring treatments for metastatic pancreatic cancer and mKRAS G12C non-small cell lung cancer (NSCLC). Interim results for Avutometinib + Defactinib show a 45% ORR overall and 60% ORR for KRAS-mutant patients, with tumor ...
Neutral
Business Wire
5 days ago
BOSTON & HOUSTON, Texas--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, and the STAAR Ovarian Cancer Foundation today announced the first Low-Grade Serous Ovarian Cancer Awareness Day or “LGSOC Awareness Day” on September 9, 2024. September is Ovarian Cancer Awareness Month and LGSOC is a rare ovarian...
Neutral
Business Wire
about one month ago
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to avutometinib, a RAF/MEK clamp, in combination with defactinib, a selective FAK inhibitor, for the treatment of pancreatic cancer. “At the ASCO 2024 A...
More Verastem, Inc. News

Company Profile

Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Head office United States
CEO Dan Paterson
Employees 73
Founded 2010
Website www.verastem.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today